Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the ...

Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...

EQS-News: Newron Pharmaceuticals S.p.A. / Key word (s): Agreement Newron and Myung In Pharm announce license agreement for evenamide in South Korea 09.01.2025 / 07:00 CET/CEST The issuer is solely ...

And it doesn’t appear to cause side-effects, such as weight gain, pacing and drowsiness — issues that force some patients taking older anti-schizophrenia drugs to abandon their medical treatment. This ...

And it doesn’t appear to cause side-effects, such as weight gain, pacing and drowsiness — issues that force some patients taking older anti-schizophrenia drugs to abandon their medical treatment.

Background: Hallucinations are prevalent in schizophrenia and related ... are fairly responsive to antipsychotic drug treatment and differential anti-hallucinatory effectiveness may be found ...

An audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com. A replay of the session will be available later that day. About Anavex Life Sciences Corp.

The schizophrenia space received a shot in the arm this year when Bristol Myers Squibb secured FDA approval for KarXT—now dubbed Cobenfy—marking the first new drug for the mental health ...

as the first anti-PD-L1 antibody for use in metastatic or locally advanced cutaneous squamous cell carcinoma patients who are not candidates for curative surgery or curative radiation. Newron stock ...